Construction and Preclinical Evaluation of a 124/125I-Labeled Specific Antibody Targeting PD-L2 in Lung Cancer
Work
Year: 2022
Type: article
Source: Molecular Pharmaceutics
Cites: 25
Cited by: 5
Related to: 10
FWCI: 0.822
Citation percentile (by year/subfield): 62.72
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: closed
Grant ID 81871387